JP7359697B2 - ジヒドロインドリジノン誘導体 - Google Patents

ジヒドロインドリジノン誘導体 Download PDF

Info

Publication number
JP7359697B2
JP7359697B2 JP2019566511A JP2019566511A JP7359697B2 JP 7359697 B2 JP7359697 B2 JP 7359697B2 JP 2019566511 A JP2019566511 A JP 2019566511A JP 2019566511 A JP2019566511 A JP 2019566511A JP 7359697 B2 JP7359697 B2 JP 7359697B2
Authority
JP
Japan
Prior art keywords
group
alkoxy
compound
salt
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019566511A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2019142883A1 (ja
JPWO2019142883A5 (https=
Inventor
俊宏 木方
辰也 矢野
聡 小森谷
太作 田中
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Daiichi Sankyo Co Ltd
Original Assignee
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd
Publication of JPWO2019142883A1 publication Critical patent/JPWO2019142883A1/ja
Publication of JPWO2019142883A5 publication Critical patent/JPWO2019142883A5/ja
Application granted granted Critical
Publication of JP7359697B2 publication Critical patent/JP7359697B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0676—Pancreatic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/39—Pancreas; Islets of Langerhans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C12N2501/73—Hydrolases (EC 3.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2019566511A 2018-01-18 2019-01-18 ジヒドロインドリジノン誘導体 Active JP7359697B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2018006269 2018-01-18
JP2018006269 2018-01-18
PCT/JP2019/001364 WO2019142883A1 (ja) 2018-01-18 2019-01-18 ジヒドロインドリジノン誘導体

Publications (3)

Publication Number Publication Date
JPWO2019142883A1 JPWO2019142883A1 (ja) 2021-01-14
JPWO2019142883A5 JPWO2019142883A5 (https=) 2022-02-07
JP7359697B2 true JP7359697B2 (ja) 2023-10-11

Family

ID=67302218

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019566511A Active JP7359697B2 (ja) 2018-01-18 2019-01-18 ジヒドロインドリジノン誘導体

Country Status (12)

Country Link
US (1) US11530211B2 (https=)
EP (1) EP3741757B1 (https=)
JP (1) JP7359697B2 (https=)
KR (1) KR20200110338A (https=)
CN (1) CN111630052B (https=)
AU (1) AU2019208634B2 (https=)
CA (1) CA3088968C (https=)
ES (1) ES2958118T3 (https=)
IL (1) IL276125A (https=)
SG (1) SG11202006837XA (https=)
TW (1) TWI818948B (https=)
WO (1) WO2019142883A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114040966A (zh) * 2019-07-08 2022-02-11 国立大学法人东京工业大学 使用了二氢吲嗪酮衍生物的胰岛素生产细胞的制作法
EP4727939A1 (en) * 2023-06-14 2026-04-22 Prothena Biosciences Limited 5-(cinnolin-6-yl)thiazole compounds for treating neurological disorders

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003128551A (ja) 2001-08-15 2003-05-08 Sankyo Co Ltd 新規抗糖尿病医薬組成物
JP2009504782A (ja) 2005-08-18 2009-02-05 アルナイラム ファーマシューティカルズ インコーポレイテッド 神経疾患を治療するための方法および組成物
JP2011518563A (ja) 2008-04-24 2011-06-30 セントコア・オーソ・バイオテツク・インコーポレーテツド 多能性細胞の処理
JP2017522347A (ja) 2014-07-31 2017-08-10 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ 神経変性疾患に適応可能なインドリジン誘導体

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR039059A1 (es) 2001-08-06 2005-02-09 Sanofi Aventis Compuesto derivado de acilaminotiazol, su utilizacion, procedimientos para prepararlo, composicion farmaceutica que lo comprende, y compuestos intermediarios
EP1999253B1 (en) 2006-03-02 2019-05-22 Viacyte, Inc. Endocrine precursor cells, pancreatic hormone-expressing cells and methods of production
EP2373645A4 (en) * 2008-12-08 2012-05-02 Sirtris Pharmaceuticals Inc ISOINDOLINONE AND RELATED ANALOGUES AS SIRTUIN MODULATORS
WO2012056997A1 (ja) 2010-10-28 2012-05-03 国立大学法人熊本大学 多能性幹細胞の分化誘導効率を改善するための方法及び培地
JPWO2012121168A1 (ja) 2011-03-04 2014-07-17 国立大学法人京都大学 キナーゼ阻害剤
AU2013255031C1 (en) 2012-04-30 2018-12-06 University Health Network Methods and compositions for generating pancreatic progenitors and functional beta cells from hPSCs
JP2014161257A (ja) 2013-02-22 2014-09-08 Univ Of Tokyo 多能性幹細胞から膵ランゲルハンス島を製造する方法
US8859286B2 (en) 2013-03-14 2014-10-14 Viacyte, Inc. In vitro differentiation of pluripotent stem cells to pancreatic endoderm cells (PEC) and endocrine cells
WO2015020113A1 (ja) 2013-08-07 2015-02-12 国立大学法人京都大学 膵ホルモン産生細胞の製造法
DK3039122T3 (da) 2013-08-30 2019-09-30 Novo Nordisk As Generering af endokrine progenitorceller fra humane pluripotente stamceller under anvendelse af små molekyler
WO2015125662A1 (ja) 2014-02-21 2015-08-27 国立大学法人熊本大学 アミノ酸組成変更培地を用いた幹細胞の分化促進方法、及び該方法を用いて処理された幹細胞、並びに培地
JP6094516B2 (ja) 2014-03-19 2017-03-15 三菱電機株式会社 エレベーター装置
US10006006B2 (en) 2014-05-16 2018-06-26 Janssen Biotech, Inc. Use of small molecules to enhance MAFA expression in pancreatic endocrine cells
US10457916B2 (en) 2014-05-20 2019-10-29 Tokyo Institute Of Technology Method for inducing differentiation of insulin-producing cells
WO2016100898A1 (en) 2014-12-18 2016-06-23 President And Fellows Of Harvard College Serum-free in vitro directed differentiation protocol for generating stem cell-derived b cells and uses thereof
CN107614678B (zh) 2014-12-18 2021-04-30 哈佛学院校长同事会 干细胞来源的β细胞的产生方法及其使用方法
WO2016100909A1 (en) 2014-12-18 2016-06-23 President And Fellows Of Harvard College METHODS FOR GENERATING STEM CELL-DERIVED β CELLS AND USES THEREOF
WO2016100921A1 (en) 2014-12-18 2016-06-23 President And Fellows Of Harvard College METHODS FOR GENERATING STEM CELL-DERIVED β CELLS AND USES THEREOF
US20160177268A1 (en) 2014-12-18 2016-06-23 President And Fellows Of Harvard College Methods for generating augmented stem cell-derived beta cells and uses thereof
CA2979293C (en) 2015-03-11 2022-01-04 Timothy J. Kieffer Pancreatic endocrine progenitor cell therapies for the treatment of obesity and type 2 diabetes (t2d)

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003128551A (ja) 2001-08-15 2003-05-08 Sankyo Co Ltd 新規抗糖尿病医薬組成物
JP2009504782A (ja) 2005-08-18 2009-02-05 アルナイラム ファーマシューティカルズ インコーポレイテッド 神経疾患を治療するための方法および組成物
JP2011518563A (ja) 2008-04-24 2011-06-30 セントコア・オーソ・バイオテツク・インコーポレーテツド 多能性細胞の処理
JP2017522347A (ja) 2014-07-31 2017-08-10 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ 神経変性疾患に適応可能なインドリジン誘導体

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BILGUVAR, K. et al.，Recessive loss of function of the neuronal ubiquitin hydrolase UCHL1 leads to early-onset progressive neurodegeneration，PNAS，2013年，110(9)，pp.3489-3494
GRAHAM, S. H. et al.，Life and death in the trash heap: The ubiquitin proteasome pathway and UCHL1 in brain aging, neurodegenerative disease and cerebral ischemia，Ageing Research Reviews，2017年，34，pp.30-38
武内 大輝 他，Ｏ－４２－５ ヒト多能性幹細胞からインスリン産生細胞への分化誘導方法の構築，再生医療，2013年，１２（Ｓｕｐｐｌ），第２０２頁
細谷 昌樹，ヒトｉＰＳ細胞からの膵β細胞分化誘導法の開発，細胞，2011年，４３（１２），第４８１－４８４頁
谷口 英樹，ＧＬＰ－１の基礎と臨床 再生医療とＧＬＰ－１，内分泌・糖尿病科，2006年，２３（３），第２６７－２７５頁

Also Published As

Publication number Publication date
AU2019208634A1 (en) 2020-08-06
EP3741757A4 (en) 2021-11-03
CN111630052B (zh) 2023-04-18
CA3088968A1 (en) 2019-07-25
TW201938156A (zh) 2019-10-01
CA3088968C (en) 2023-10-17
EP3741757B1 (en) 2023-07-26
AU2019208634A2 (en) 2020-09-24
US20210053965A1 (en) 2021-02-25
CN111630052A (zh) 2020-09-04
IL276125A (en) 2020-08-31
AU2019208634B2 (en) 2024-06-13
TWI818948B (zh) 2023-10-21
SG11202006837XA (en) 2020-08-28
JPWO2019142883A1 (ja) 2021-01-14
US11530211B2 (en) 2022-12-20
EP3741757A1 (en) 2020-11-25
ES2958118T3 (es) 2024-02-01
WO2019142883A1 (ja) 2019-07-25
KR20200110338A (ko) 2020-09-23

Similar Documents

Publication Publication Date Title
US11274077B2 (en) 4-((2-hydroxy-3-methoxybenzyl)amino)benzenesulfonamide derivatives as potent and selective inhibitors of 12-lipoxygenase
US20120135997A1 (en) Pharmaceutical composition comprising a lactam or benzenesulfonamide compound
EP2485735B1 (en) Inhibitors of fatty acid binding protein (fabp)
RU2449998C2 (ru) Ингибиторы gsk-3
JP2013503838A (ja) 糖尿病の処置のためのｂａｃｅ２阻害剤としての２−アミノジヒドロ［１，３］チアジン
JP2014509616A (ja) 治療用イミダゾ［１，２−ａ］ピリジン化合物
JP7359697B2 (ja) ジヒドロインドリジノン誘導体
JP2022528155A (ja) 糖尿病ならびに膵臓機能障害に関連する他の病気の治療のための選択的ｆｏｘｏ阻害剤
WO2021149767A1 (ja) ヘテロ環誘導体
WO2005028453A1 (ja) フェニル酢酸誘導体、その製造方法および用途
JP7553030B2 (ja) ジヒドロインドリジノン誘導体を用いたインスリン産生細胞の作製法
HK40031650A (en) Dihydroindolizinone derivative
HK40031650B (en) Dihydroindolizinone derivative
HK40066575A (en) Method for producing insulin-producing cell using dihydroindolizinone derivatives
TW202014191A (zh) 具有選擇性ｂａｃｅ１抑制活性的四氫哌喃并衍生物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220113

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220113

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230105

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230301

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230412

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230619

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230727

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230911

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230928

R150 Certificate of patent or registration of utility model

Ref document number: 7359697

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150